Suppr超能文献

肛管Ⅰ期鳞状细胞癌的治疗。

Management of Stage I Squamous Cell Carcinoma of the Anal Canal.

机构信息

Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Houston Veterans Affairs (VA) Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas.

出版信息

JAMA Surg. 2018 Mar 1;153(3):209-215. doi: 10.1001/jamasurg.2017.3151.

Abstract

IMPORTANCE

The incidence of squamous cell carcinoma of the anal canal (SCCAC) is increasing. Although standard management of SCCAC includes the use of concurrent chemotherapy and radiotherapy (chemoradiotherapy), data are lacking on potentially less morbid, alternative management strategies, such as local excision, among patients with node-negative T1 disease.

OBJECTIVES

To examine the use of local excision among patients with T1 SCCAC and to compare overall survival relative to those who received standard treatment with chemoradiotherapy.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed 2243 patients in the National Cancer Database (2004-2012) between 18 and 80 years of age with T1N0M0 SCCAC. The association between the type of treatment received and overall risk of death was evaluated using multivariable Cox proportional hazards regression models. Data analysis was performed from June 29, 2016, to April 17, 2017.

MAIN OUTCOMES AND MEASURES

Overall survival.

RESULTS

Among 2243 patients with T1N0 SCCAC, 503 (22.4%) were treated with local excision alone (mean [SD] age, 54.5 [12.1] years; 240 [47.7%] male; 419 [83.3%] white) and 1740 with chemoradiotherapy (mean [SD] age, 57.0 [10.6] years; 562 [32.3%] male; 1547 [88.9%] white). Among those treated with chemoradiotherapy, 12 patients underwent a subsequent abdominoperineal resection. There was a statistically significant increase in the use of local excision during the study period (34 [17.3%] in 2004 to 68 [30.8%] in 2012; trend test,  < .001). This increase in use was observed among patients with primary tumors that measured 1 cm or smaller and greater than 1 cm to 2 cm or smaller (trend test,  < .001 for both). Overall survival at 5 years was not significantly different for the 2 management strategies (85.3% in the local excision cohort and 86.8% in the chemoradiotherapy cohort; log-rank test,  = .93). Overall risk of death was not significantly different for local excision alone relative to that for treatment with chemoradiotherapy (hazard ratio, 1.06; 95% CI, 0.78-1.44). These findings were robust when stratified by tumor size and when patients who underwent abdominoperineal resection after chemoradiotherapy were excluded.

CONCLUSIONS AND RELEVANCE

The use of local excision alone for the management of T1N0 SCCAC has significantly increased over time, with no clear decrement in overall survival. Because local excision may represent a lower-cost, less morbid treatment option for select patients with SCCAC, future studies are needed to better delineate its role and efficacy relative to the current standard of chemoradiotherapy.

摘要

重要性

肛门管鳞癌 (SCCAC) 的发病率正在上升。虽然 SCCAC 的标准治疗包括使用同期化疗和放疗(放化疗),但缺乏数据表明在 T1 期无淋巴结转移的患者中,局部切除等潜在风险较低的替代治疗策略的效果,例如局部切除。

目的

研究 T1 SCCAC 患者中局部切除的应用,并比较与接受放化疗标准治疗的患者的总生存率。

设计、设置和参与者:本回顾性队列研究评估了国家癌症数据库(2004-2012 年)中的 2243 名年龄在 18 至 80 岁之间的 T1N0M0 SCCAC 患者。使用多变量 Cox 比例风险回归模型评估接受的治疗类型与死亡风险之间的关联。数据分析于 2016 年 6 月 29 日至 2017 年 4 月 17 日进行。

主要结果和措施

总生存率。

结果

在 2243 名 T1N0 SCCAC 患者中,503 名(22.4%)单独接受局部切除治疗(平均[标准差]年龄为 54.5[12.1]岁;240[47.7%]为男性;419[83.3%]为白人),1740 名接受放化疗(平均[标准差]年龄为 57.0[10.6]岁;562[32.3%]为男性;1547[88.9%]为白人)。在接受放化疗的患者中,有 12 名患者随后接受了腹会阴联合切除术。研究期间局部切除的使用率呈显著上升趋势(2004 年为 34[17.3%],2012 年为 68[30.8%];趋势检验, < .001)。在原发肿瘤直径为 1cm 或以下和大于 1cm 至 2cm 或以下的患者中观察到这种使用率的增加(趋势检验,两者均 < .001)。两种治疗策略的 5 年总生存率无显著差异(局部切除组为 85.3%,放化疗组为 86.8%;对数秩检验, = .93)。与放化疗相比,单独局部切除的总死亡风险无显著差异(风险比,1.06;95%CI,0.78-1.44)。当按肿瘤大小分层时,当排除接受放化疗后行腹会阴联合切除术的患者后,这些发现仍然稳健。

结论和相关性

单独使用局部切除治疗 T1N0 SCCAC 的方法已显著增加,且总生存率无明显下降。由于局部切除可能代表了一种对 SCCAC 患者来说风险较低、成本较低的治疗选择,因此需要进一步的研究来更好地阐明其相对于当前放化疗标准的作用和疗效。

相似文献

1
Management of Stage I Squamous Cell Carcinoma of the Anal Canal.肛管Ⅰ期鳞状细胞癌的治疗。
JAMA Surg. 2018 Mar 1;153(3):209-215. doi: 10.1001/jamasurg.2017.3151.
5
Combination therapy for epidermoid carcinoma of the anal canal.肛管表皮样癌的联合治疗
Dis Colon Rectum. 1994 Nov;37(11):1118-25. doi: 10.1007/BF02049814.
6
Epidermoid cancer of the anus.肛门表皮样癌
Br J Surg. 1985 Sep;72 Suppl:S97-103. doi: 10.1002/bjs.1800721350.
8
An update on anal cancer diagnosis and treatment.肛门癌诊断与治疗的最新进展。
Pol Przegl Chir. 2011 Feb;83(2):108-16. doi: 10.2478/v10035-011-0018-4.
9
Anal cancers. Squamous and melanoma.肛管癌。鳞状细胞癌和黑色素瘤。
Cancer. 1992 Sep 1;70(5 Suppl):1384-9. doi: 10.1002/1097-0142(19920901)70:3+<1384::aid-cncr2820701528>3.0.co;2-0.
10
Surgical management of anal cancer.肛管癌的外科治疗
Minerva Chir. 2015 Apr;70(2):141-5. Epub 2015 Feb 18.

引用本文的文献

8
Anal Cancer: The Past, Present and Future.肛门癌:过去、现在和未来。
Curr Oncol. 2023 Mar 11;30(3):3232-3250. doi: 10.3390/curroncol30030246.

本文引用的文献

3
Anal cancer - What is the optimum chemoradiotherapy?肛管癌——最佳的放化疗方案是什么?
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):641-53. doi: 10.1016/j.bpg.2016.06.005. Epub 2016 Jun 30.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验